Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions

B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Lymphoblastic Lymphoma | T-cell Adult Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

What is the purpose of this trial?

This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells.



Participation Guidelines

Age:
1 Year - 31 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
March 2009
Last Updated:
September 30, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00873093